參考文獻(xiàn)/References:
[1] Xu L,Sun X,Ma X.Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae[J].Ann Clin Microbiol Antimicrob,2017,16(1):18.[2] Huang W,Qiao F,Zhang Y,et al.In-hospital medical costs of infections caused by carbapenem-resistant Klebsiella pneumoniae[J].Clin Infect Dis,2018,67(2):225-230. [3] Duin D V,Bonomo R A.Ceftazidime/avibactam and ceftolozane/tazobactam:second-generation β-lactam/β-lactamase inhibitor combinations[J].Clin Infect Dis,2016,63(2):234-241.[4] Humphries R M,Hemarajata P.Resistance to eftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3[J].Antimicrob Agents Chemother,2017,61(6):e00537-17.[5] 葉相如,胡必杰,周春妹,等.耐碳青霉烯類肺炎克雷伯菌感染與定植患者預(yù)后相關(guān)因素分析[J].中華醫(yī)院感染學(xué)雜志,2015(11):2489-2491.[6] 孫吉,何鴿飛,沈暉,等.耐碳青霉烯類肺炎克雷伯菌的藥敏結(jié)果及耐藥基因[J].中國感染控制雜志,2019,18(6):489-494.[7] Li J,Li Y,Song N,et al.Risk factors for carbapenem-resistant Klebsiella pneumoniae infection:a meta-analysis[J].J Glob Antimicrob Resist,2020(21):306-313.[8] Zhang P,Shi Q,Hu H,et al.Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneu-moniae in China[J].Clin Microbiol Infect,2020,26(1):124.e1-124.e4.[9] David S,Reuter S,Harris S R,et al.Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread[J].Nat Microbiol,2019,4(11):1919-1929.[10] Kitchel B,Rasheed J K,Patel J B,et al.Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States:clonal expansion of multilocus sequence type 258[J].Antimicrob Agents Chemother,2009,53(8):3365-3370.[11] Gu D,Dong N,Zheng Z,et al.A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital:a molecular epidemiological study[J].Lancet Infect Dis,2018,18(1):37-46.[12] 趙錦錦.頭孢他啶-阿維巴坦藥品說明書[J].國外醫(yī)藥抗生素分冊,2019,40(2):115-127.[13] Kazmierczak K M,Rabine S,Hackel M,et al.Multiyear,multinational survey of the incidence and global distribution of metallo-β-lactamase-producing enterobacteriaceae and pseudomonas aeruginosa[J].Antimicrob Agents Chemother,2016,60(2):1067-1078.[14] Liu Y,Zhang H,Zhang X,et al.Characterization of an NDM-19-producing Klebsiella pneumoniae strain harboring 2 resistance plasmids from China[J].Diagn Microbiol Infect Dis,2019,93(4):355-361.[15] Lauretti L,Riccio M L,Mazzariol A,et al. Cloning and characterization of blaVIM,a new integron-borne metallo-beta-lactamase gene from a pseudomonas aeruginosa clinical isolate[J].Antimicrob Agents Chemother,1999,43(7):1584-1590.[16] Peirano G,Lascols C,Hackel M,et al. Molecular epidemio-logy of enterobacteriaceae that produce VIMs and IMPs from the SMART surveillance program[J].Diagn Microbiol Infect Dis,2014,78(3):277-281.[17] Nelson K,Hemarajata P,Sun D,et al.Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity[J].Antimicrob Agents Chemother,2017,61(10):e00989-17.